Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01211678 · ClinicalTrials.gov registry record
Biomarkers of Anti-TNF-α Therapy Efficacy in Rheumatoid Arthritis to Define Unresponsive Patients
A clinical trial, sponsored by Biogen.
- Completed
- Registry status
- 301
- Enrollment target
NCT01211678 is a clinical trial that has completed, run by Biogen. The registered enrollment target is 301 participants.
The verdict
NCT01211678 has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- 301 participants
- Enrollment target
Study Summary
The primary objective of this study was to validate the ability of an 8-gene biomarker set to differentiate between participants who met or did not meet European League Against Rheumatism (EULAR) Disease Activity Score (DAS)-28 Good Response criteria after treatment with anti-Tumor Necrosis Factor (TNF) therapy for 14 weeks in approximately 200 anti-TNF-naïve participants. The secondary objectives of this study was (i) to compare the behavior of the 8-gene marker set in participants who were anti-TNF naïve versus those who began their second anti-TNF treatment , (ii) to develop, maintain, and utilize a biorepository of serum, plasma, RNA, and deoxyribonucleic acid (DNA) samples for additional experiments and analyses and (iii) to discover novel genetic (DNA) predictors of response to anti-TNF therapy.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 301 participants |
| Start Date | 2010-06 |
| Est. Completion | 2013-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01211678
The ClinicalTrials.gov registry entry for NCT01211678 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 301 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01211678 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01211678 about?
NCT01211678 is a clinical study titled "Biomarkers of Anti-TNF-α Therapy Efficacy in Rheumatoid Arthritis to Define Unresponsive Patients". The primary objective of this study was to validate the ability of an 8-gene biomarker set to differentiate between participants who met or did not meet European League Against Rheumatism (EULAR) Disease Activity Score (DAS)-28 Good Response criteria after treatment with anti-Tumor Necrosis Factor (...
What is the current status of trial NCT01211678?
This trial is currently completed. The enrollment target is 301 participants. The study started on 2010-06. Estimated completion is 2013-07.
Who is sponsoring clinical trial NCT01211678?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.